» Articles » PMID: 30806044

Chlorotoxin Targets ERα/VASP Signaling Pathway to Combat Breast Cancer

Overview
Journal Cancer Med
Specialty Oncology
Date 2019 Feb 27
PMID 30806044
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is one of the most common malignant tumors among women worldwide. About 70-75% of primary breast cancers belong to estrogen receptor (ER)-positive breast cancer. In the development of ER-positive breast cancer, abnormal activation of the ERα pathway plays an important role and is also a key point leading to the failure of clinical endocrine therapy. In this study, we found that the small molecule peptide chlorotoxin (CTX) can significantly inhibit the proliferation, migration and invasion of breast cancer cells. In in vitro study, CTX inhibits the expression of ERα in breast cancer cells. Further studies showed that CTX can directly bind to ERα and change the protein secondary structure of its LBD domain, thereby inhibiting the ERα signaling pathway. In addition, we also found that vasodilator stimulated phosphoprotein (VASP) is a target gene of ERα signaling pathway, and CTX can inhibit breast cancer cell proliferation, migration, and invasion through ERα/VASP signaling pathway. In in vivo study, CTX significantly inhibits growth of ER overexpressing breast tumor and, more importantly, based on the mechanism of CTX interacting with ERα, we found that CTX can target ER overexpressing breast tumors in vivo. Our study reveals a new mechanism of CTX anti-ER-positive breast cancer, which also provides an important reference for the study of CTX anti-ER-related tumors.

Citing Articles

Venom-derived peptides for breaking through the glass ceiling of drug development.

Freuville L, Matthys C, Quinton L, Gillet J Front Chem. 2024; 12:1465459.

PMID: 39398192 PMC: 11468230. DOI: 10.3389/fchem.2024.1465459.


Harnessing the potency of scorpion venom-derived proteins: applications in cancer therapy.

El-Qassas J, Abd El-Atti M, El-Badri N Bioresour Bioprocess. 2024; 11(1):93.

PMID: 39361208 PMC: 11450130. DOI: 10.1186/s40643-024-00805-0.


Diagnostic and Therapeutic Approaches for Glioblastoma and Neuroblastoma Cancers Using Chlorotoxin Nanoparticles.

Boltman T, Meyer M, Ekpo O Cancers (Basel). 2023; 15(13).

PMID: 37444498 PMC: 10341066. DOI: 10.3390/cancers15133388.


The Structure, Function and Regulation of Protein Tyrosine Phosphatase Receptor Type J and Its Role in Diseases.

Li H, Zhang P, Liu C, Wang Y, Deng Y, Dong W Cells. 2023; 12(1).

PMID: 36611803 PMC: 9818648. DOI: 10.3390/cells12010008.


Reptiles as Promising Sources of Medicinal Natural Products for Cancer Therapeutic Drugs.

Park S, Choi H, Chung J Pharmaceutics. 2022; 14(4).

PMID: 35456708 PMC: 9025323. DOI: 10.3390/pharmaceutics14040874.


References
1.
Su K, Tian Y, Wang J, Shi W, Luo D, Liu J . HIF-1α acts downstream of TNF-α to inhibit vasodilator-stimulated phosphoprotein expression and modulates the adhesion and proliferation of breast cancer cells. DNA Cell Biol. 2012; 31(6):1078-87. DOI: 10.1089/dna.2011.1563. View

2.
Karalis T, Heldin P, Vynios D, Neill T, Buraschi S, Iozzo R . Tumor-suppressive functions of 4-MU on breast cancer cells of different ER status: Regulation of hyaluronan/HAS2/CD44 and specific matrix effectors. Matrix Biol. 2018; 78-79:118-138. DOI: 10.1016/j.matbio.2018.04.007. View

3.
Musgrove E, Sutherland R . Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9(9):631-43. DOI: 10.1038/nrc2713. View

4.
Kesavan K, Ratliff J, Johnson E, Dahlberg W, Asara J, Misra P . Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem. 2009; 285(7):4366-74. PMC: 2836041. DOI: 10.1074/jbc.M109.066092. View

5.
Jacoby D, Dyskin E, Yalcin M, Kesavan K, Dahlberg W, Ratliff J . Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide. Anticancer Res. 2010; 30(1):39-46. View